Art. -Nr.: HY-19829

Sandramycin

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 100940-65-6
Formel: C₆₀H₇₆N₁₂O₁₆
Molecular Weight:1221.32

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

Sandramycin Chemical Structure

CAS. Nr.: 100940-65-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

One-stop CDMO Service

One-Stop Platform：From Independent R&D to Pilot-Scale Production

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Traditional Cytotoxic Agents

Alle ADC Payloads Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	8 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma) The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)	10.1016/S0960-894X(97)00129-7
B16	IC₅₀	0.4 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma) The compound was tested in vitro for cytotoxic activity against B-16 cell line (mouse melanoma)	10.1016/S0960-894X(97)00129-7
BT-549	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma) The compound was tested in vitro for cytotoxic activity against BT-549 cell line (human breast carcinoma)	10.1016/S0960-894X(97)00129-7
EBC-1	IC₅₀	1.4 nM Compound: Sandramycin	Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human EBC-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
H322	IC₅₀	20 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma) The compound was tested in vitro for cytotoxic activity against H 322 cell line (human lung adenocarcinoma)	10.1016/S0960-894X(97)00129-7
HL-60	IC₅₀	80 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia) The compound was tested in vitro for cytotoxic activity against HL-60 cell line (human promyelomic leukemia)	10.1016/S0960-894X(97)00129-7
HT-29	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma) The compound was tested in vitro for cytotoxic activity against HT-29 cell line (human colon adenocarcinoma)	10.1016/S0960-894X(97)00129-7
IGROV-1	IC₅₀	1.6 nM Compound: Sandramycin	Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human IGROV-1 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
L1210	IC₅₀	0.02 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia) The compound was tested in vitro for cytotoxic activity against L1210 cell line (mouse leukemia)	10.1016/S0960-894X(97)00129-7
MCF7	IC₅₀	300 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma) The compound was tested in vitro for cytotoxic activity against MCF-7 cell line (human breast carcinoma)	10.1016/S0960-894X(97)00129-7
MOLT-4	IC₅₀	0.7 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia) The compound was tested in vitro for cytotoxic activity against Molt-4 cell line (human T-cell leukemia)	10.1016/S0960-894X(97)00129-7
OVCAR-3	IC₅₀	1 nM Compound: Sandramycin	Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell growth incubated for 5 days by CellTiter-Glo luminescence assay	[PMID: 37307297]
OVCAR-3	IC₅₀	4 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma) The compound was tested in vitro for cytotoxic activity against OVCAR-3 cell line (human ovarian carcinoma)	10.1016/S0960-894X(97)00129-7
PC-3	IC₅₀	0.2 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma) The compound was tested in vitro for cytotoxic activity against PC-3 cell line (human prostate carcinoma)	10.1016/S0960-894X(97)00129-7
SiHa	IC₅₀	0.3 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma) The compound was tested in vitro for cytotoxic activity against SIHA cell line (human cervix carcinoma)	10.1016/S0960-894X(97)00129-7
SK-MEL-28	IC₅₀	1 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma) The compound was tested in vitro for cytotoxic activity against SK-MEL 28 cell line (human melanoma)	10.1016/S0960-894X(97)00129-7
UCLA P-3	IC₅₀	10 nM Compound: 1 (Sandramycin)	The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma) The compound was tested in vitro for cytotoxic activity against UCLA-P3 cell line (human lung adenocarcinoma)	10.1016/S0960-894X(97)00129-7

In Vitro

Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec⁺) A22508-2, B. subtilis (Rec^-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively^[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC₅₀ values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CDF1 female mice injected with leukemia P388 cells^[1]
Dosage:

0.0125 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.4 mg/kg, 0.8 mg/kg, 1.6 mg/kg
Administration:

Intraperitoneal injection; daily; for 5 days
Result:

Was moderately active in vivo against leukemia P388 in mice.

Chemical Information

CAS. Nr. 100940-65-6
Molecular Weight 1221.32
Formel C₆₀H₇₆N₁₂O₁₆
SMILES

CC(C)[C@@H](C(OC[C@@H](NC(C1=C(O)C=C(C=CC=C2)C2=N1)=O)C3=O)=O)N(C)C(CN(C)C(CNC([C@@H]4CCCCN4C([C@@H](COC([C@H](C(C)C)N(C)C(CN(C)C(CNC([C@H]5N3CCCC5)=O)=O)=O)=O)NC(C6=C(O)C=C(C=CC=C7)C7=N6)=O)=O)=O)=O)=O
Structure Classification
- Antibiotics
- Other Antibiotics
Initial Source
- Microorganisms
Nocardioides sp.
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. J A Matson, et al. Sandramycin, a Novel Antitumor Antibiotic Produced by a Nocardioides Sp. Production, Isolation, Characterization and Biological Properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7. [Content Brief]

[2]. Katsushi Katayama, et al. Total Synthesis of Sandramycin and Its Analogues via a Multicomponent Assemblage. Org Lett. 2014 Jan 17;16(2):428-31. [Content Brief]

[3]. D L Boger, et al. DNA Binding Properties of Key Sandramycin Analogues: Systematic Examination of the Intercalation Chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Sandramycin

Alle ADC Payloads Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Sandramycin Related Classifications

HY-19829 Related Classifications